About
Our Story
Our People
Our Advisors
Science
Pipeline
Izokibep
Lonigutamab
SLRN-517
Presentations & Publications
Community
Patients
Partnerships
Investors & Media
Overview
Press Releases
Events & Presentations
Financials & Filings
Corporate Governance
Email Alerts
Investor Resources
Media Resources
Careers
Stories
Contact Us
Presentation
Izokibep Demonstrates HiSCR100 Reponses in Moderate-to-Severe Hidradenitis Suppurativa at Week 12
March 29, 2023
Share
Izokibep Demonstrates HiSCR100 Reponses in Moderate-to-Severe Hidradenitis Suppurativa at Week 12
Copy
